Literature DB >> 30709505

Signaling Molecules in Posttransplantation Cancer.

Murugabaskar Balan1, Samik Chakraborty1, Soumitro Pal2.   

Abstract

Immunosuppression is essential to prevent graft rejection. However, immunosuppression impairs the ability of the host immune system to control viral infection and decreases tumor immunosurveillance. Therefore, immunosuppression after organ transplantation is a major risk factor for posttransplantation cancer. Notably, recent reports suggest that immunosuppressive agents can activate tumorigenic pathways independent of the involvement of the host immune system. In this review, we focus on cell-intrinsic tumorigenic pathways directly activated by immunosuppressive agents and discuss the much-described infection- and immune-mediated mechanisms of cancer development in organ transplant recipients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CNI; Immunosuppression; Posttransplantation cancer; Risk factor; Signaling mechanisms

Mesh：

Substances：

Year:  2018        PMID： 30709505      PMCID： PMC6368395          DOI： 10.1016/j.cll.2018.10.006

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  24 in total

Review 1.  Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types.

Authors:  Caroline P Perez; Neha Patel; Caitlin R Mardis; Holly B Meadows; David J Taber; Nicole A Pilch
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 2.  Cancer in kidney transplant recipients.

Authors:  Eric Au; Germaine Wong; Jeremy R Chapman
Journal:  Nat Rev Nephrol       Date:  2018-08       Impact factor: 28.314

Review 3.  Novel approaches to preventing ischemia-reperfusion injury during liver transplantation.

Authors:  M Z Akhtar; T Henderson; A Sutherland; T Vogel; P J Friend
Journal:  Transplant Proc       Date:  2013 Jul-Aug       Impact factor: 1.066

4.  Cyclosporine induces cancer progression by a cell-autonomous mechanism.

Authors:  M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran
Journal:  Nature       Date:  1999-02-11       Impact factor: 49.962

5.  Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.

Authors:  Mathias Thurau; Gaby Marquardt; Nathalie Gonin-Laurent; Kristina Weinländer; Elisabeth Naschberger; Ramona Jochmann; Khaled R Alkharsah; Thomas F Schulz; Margot Thome; Frank Neipel; Michael Stürzl
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 6.  Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.

Authors:  Andreas Gaumann; Hans J Schlitt; Edward K Geissler
Journal:  Transpl Int       Date:  2007-12-05       Impact factor: 3.782

Review 7.  The role of hypoxia-inducible factors in organ donation and transplantation: the current perspective and future opportunities.

Authors:  M Z Akhtar; A I Sutherland; H Huang; R J Ploeg; C W Pugh
Journal:  Am J Transplant       Date:  2014-06-06       Impact factor: 8.086

8.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

9.  Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.

Authors:  Aninda Basu; Pallavi Banerjee; Alan G Contreras; Evelyn Flynn; Soumitro Pal
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.

Authors:  Ben Sprangers; Vinay Nair; Vincent Launay-Vacher; Leonardo V Riella; Kenar D Jhaveri
Journal:  Clin Kidney J       Date:  2017-10-27
View more
  2 in total

1.  A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation.

Authors:  Akash Sabarwal; Johannes Wedel; Kaifeng Liu; David Zurakowski; Samik Chakraborty; Evelyn Flynn; David M Briscoe; Murugabaskar Balan; Soumitro Pal
Journal:  Carcinogenesis       Date:  2022-05-19       Impact factor: 4.741

2.  A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.

Authors:  Akash Sabarwal; Samik Chakraborty; Simran Mahanta; Selina Banerjee; Murugabaskar Balan; Soumitro Pal
Journal:  Cancers (Basel)       Date:  2020-07-03       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.